Peter Bedner
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Peter Bedner has a total of 84 co-authors. Here are the top co-authors by number of shared publications:
- Christian Steinhäuser
Institute of Cellular Neurosciences I, Medical Faculty University of Bonn Bonn Germany
18 shared publications Lukas Henning
Institute of Cellular Neurosciences I University of Bonn, University Hospital Bonn Bonn Germany
9 shared publicationsGerald Seifert
Institute of Cellular Neurosciences I, Medical Faculty, University of Bonn, Bonn, Germany
4 shared publicationsJulia Müller
Institute of Cellular Neurosciences, Medical Faculty University of Bonn Bonn Germany
4 shared publications- Gerald Seifert
Institute of Cellular Neurosciences I University of Bonn, University Hospital Bonn Bonn Germany
3 shared publications Bernd K. Fleischmann
Institute of Physiology I, Medical Faculty, University of Bonn, Bonn, Germany
2 shared publications
Latest Publications
- Open Access
Deletion of Astrocytic TNFR1 Attenuates Hyperexcitability and Initiation of Epileptogenesis
Temporal lobe epilepsy (TLE), the most common form of adult focal epilepsy, is highly resistant to current medical therapy. Cytokine signaling, including via tumor necrosis factor‐alpha (TNFα), has been implicated not only as an accompanying factor but as a key aspect in the initiation of the disease. TNFα, through its type‐1 receptor (TNFR1) in astrocytes, controls excitatory circuits in the hippocampus, yet it remains unknown whether this astrocyte pathway specifically contributes to epilepsy. Here, we used a conditional cell‐specific knockout mouse line to induce TNFR1 deletion selectively in astrocytes and test its roles in the initiation and progression of TLE. Mice lacking astrocyte TNFR1 showed decreased basal spectral power, longer latency to first seizure following treatment with kainic acid, and a less severe phenotype up to 4 weeks later. Thus, abrogation of astrocyte TNFR1 signaling may be beneficial in TLE and could provide a new therapeutic target for this disease.
Open AccessDeletion of Astrocytic TNFR1 Attenuates Hyperexcitability and Initiation of Epileptogenesis
Temporal lobe epilepsy (TLE), the most common form of adult focal epilepsy, is highly resistant to current medical therapy. Cytokine signaling, including via tumor necrosis factor‐alpha (TNFα), has been implicated not only as an accompanying factor but as a key aspect in the initiation of the disease. TNFα, through its type‐1 receptor (TNFR1) in astrocytes, controls excitatory circuits in the hippocampus, yet it remains unknown whether this astrocyte pathway specifically contributes to epilepsy. Here, we used a conditional cell‐specific knockout mouse line to induce TNFR1 deletion selectively in astrocytes and test its roles in the initiation and progression of TLE. Mice lacking astrocyte TNFR1 showed decreased basal spectral power, longer latency to first seizure following treatment with kainic acid, and a less severe phenotype up to 4 weeks later. Thus, abrogation of astrocyte TNFR1 signaling may be beneficial in TLE and could provide a new therapeutic target for this disease.
- Open Access
- 5 February 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (3) , 1589
LRRC8-Mediated Glutamate Release from Astrocytes Is Not Increased During the Initiation of Experimental Temporal Lobe Epilepsy
LRRC8 channels are volume-regulated anion channels (VRACs) activated by cellular swelling, which mediate regulatory volume decrease in many cell types. Recently, it has been shown that these channels contribute to the release of glutamate from astrocytes. Since enhanced extracellular glutamate concentrations produce hyperexcitability, and microdialysis revealed elevated levels of the transmitter in the brains of epileptic patients, we asked whether astroglial glutamate release through LRRC8/VRACs might contribute to the initiation of experimental temporal lobe epilepsy (TLE). Patch clamp, pharmacological, and single-cell transcript analyses were performed in the hippocampus of controls and mice with inducible deletion of LRRC8a in astrocytes. In addition, these mice were exposed to our unilateral intracortical kainate model of TLE. Tonic currents were recorded from CA1 pyramidal neurons as a measure of glutamate release. Our data show that neither expression of LRRC8a nor the amplitude of tonic currents was altered 4 h after status epilepticus-induced TLE. These findings do not suggest that increased astroglial glutamate release through LRRC8 channels contributes to the initiation of experimental TLE.
- 5 February 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (3) , 1589
Open AccessLRRC8-Mediated Glutamate Release from Astrocytes Is Not Increased During the Initiation of Experimental Temporal Lobe Epilepsy
LRRC8 channels are volume-regulated anion channels (VRACs) activated by cellular swelling, which mediate regulatory volume decrease in many cell types. Recently, it has been shown that these channels contribute to the release of glutamate from astrocytes. Since enhanced extracellular glutamate concentrations produce hyperexcitability, and microdialysis revealed elevated levels of the transmitter in the brains of epileptic patients, we asked whether astroglial glutamate release through LRRC8/VRACs might contribute to the initiation of experimental temporal lobe epilepsy (TLE). Patch clamp, pharmacological, and single-cell transcript analyses were performed in the hippocampus of controls and mice with inducible deletion of LRRC8a in astrocytes. In addition, these mice were exposed to our unilateral intracortical kainate model of TLE. Tonic currents were recorded from CA1 pyramidal neurons as a measure of glutamate release. Our data show that neither expression of LRRC8a nor the amplitude of tonic currents was altered 4 h after status epilepticus-induced TLE. These findings do not suggest that increased astroglial glutamate release through LRRC8 channels contributes to the initiation of experimental TLE.
- 15 October 2025
- Published by Taylor & Francis
- p. 145-157
Critical Role of Astrocytes in the Development of Epilepsy
Epilepsy is a disease characterized by the periodic and unpredictable occurrence of recurrent unprovoked seizures, affecting about 1% of the world’s population. A seizure is defined as a transient occurrence of signs and/or symptoms due to abnormal excessive or synchronous neuronal activity in the brain. Even with optimal antiepileptic drug (AED) therapy, about one-third of patients have poor seizure control and become medically refractory. Currently available AEDs act on neurons, influencing voltage-gated ion channels, increasing inhibition or dampening excitation, which often leads to unwanted side effects. Thus, there is an urgent need for the development of more specific AEDs that not only act symptomatically but target the functional abnormalities responsible for the disease. In this regard, recent developments in the understanding of glial (especially astrocytic) changes in epileptogenesis might identify novel therapeutic approaches. According to recent definitions, the term “epileptogenesis” includes processes that render the brain susceptible to spontaneous recurrent seizures and to processes that intensify seizures and make them more refractory to therapy (progression). Indeed, expression and function of various channels, transporters und signalling molecules in astrocytes are altered in epilepsy. In this chapter, we focus on the crucial role of impaired K+ and glutamate homeostasis as well as altered gap junction coupling in the aetiology of mesial temporal lobe epilepsy, the most common form of epilepsy in adults, which is characterized by a particularly high therapy resistance.
- 15 October 2025
- Published by Taylor & Francis
- p. 145-157
Critical Role of Astrocytes in the Development of Epilepsy
Epilepsy is a disease characterized by the periodic and unpredictable occurrence of recurrent unprovoked seizures, affecting about 1% of the world’s population. A seizure is defined as a transient occurrence of signs and/or symptoms due to abnormal excessive or synchronous neuronal activity in the brain. Even with optimal antiepileptic drug (AED) therapy, about one-third of patients have poor seizure control and become medically refractory. Currently available AEDs act on neurons, influencing voltage-gated ion channels, increasing inhibition or dampening excitation, which often leads to unwanted side effects. Thus, there is an urgent need for the development of more specific AEDs that not only act symptomatically but target the functional abnormalities responsible for the disease. In this regard, recent developments in the understanding of glial (especially astrocytic) changes in epileptogenesis might identify novel therapeutic approaches. According to recent definitions, the term “epileptogenesis” includes processes that render the brain susceptible to spontaneous recurrent seizures and to processes that intensify seizures and make them more refractory to therapy (progression). Indeed, expression and function of various channels, transporters und signalling molecules in astrocytes are altered in epilepsy. In this chapter, we focus on the crucial role of impaired K+ and glutamate homeostasis as well as altered gap junction coupling in the aetiology of mesial temporal lobe epilepsy, the most common form of epilepsy in adults, which is characterized by a particularly high therapy resistance.
- Open Access
- 10 October 2025
- Published by Springer Nature in Neurochemical Research
- Vol. 50 (5) , 1-4
Correction: Induced Overexpression of Connexin43 in Astrocytes Attenuates the Progression of Experimental Temporal Lobe Epilepsy
- 10 October 2025
- Published by Springer Nature in Neurochemical Research
- Vol. 50 (5) , 1-4
Open AccessCorrection: Induced Overexpression of Connexin43 in Astrocytes Attenuates the Progression of Experimental Temporal Lobe Epilepsy
- Open Access
- 18 September 2025
- Published by Springer Nature in Neurochemical Research
- Vol. 50 (5) , 1-17
Induced Overexpression of Connexin43 in Astrocytes Attenuates the Progression of Experimental Temporal Lobe Epilepsy
Astrocytic gap junctional communication plays a critical role in regulating neuronal activity and network synchronization, yet its precise contributions to brain function and the pathogenesis of neurological disorders remains incompletely understood. To address this, we generated a transgenic mouse line with inducible, astrocyte-specific overexpression of the gap junction protein connexin43 (Cx43). In these mice, hippocampal astrocytes exhibited markedly elevated Cx43 protein levels and a ~ 20% increase in intercellular gap junction coupling. Enhanced coupling was accompanied by a reduction in astrocytic cell volume and branching, without affecting passive membrane properties or astrocyte density in the hippocampus. Cx43 overexpression had no detectable impact on adult neurogenesis in the dentate gyrus, nor did it alter hippocampal synaptic efficacy or plasticity. Notably, in a mouse model of temporal lobe epilepsy with hippocampal sclerosis, astrocytic Cx43 overexpression attenuated chronic epileptic activity and the extent of sclerosis, supporting an antiepileptic role of the astroglial network. Collectively, these findings enhance our understanding of the functional relevance of astrocytic gap junction coupling in health and disease, with potential implications for the design of new treatment strategies.
- 18 September 2025
- Published by Springer Nature in Neurochemical Research
- Vol. 50 (5) , 1-17
Open AccessInduced Overexpression of Connexin43 in Astrocytes Attenuates the Progression of Experimental Temporal Lobe Epilepsy
Astrocytic gap junctional communication plays a critical role in regulating neuronal activity and network synchronization, yet its precise contributions to brain function and the pathogenesis of neurological disorders remains incompletely understood. To address this, we generated a transgenic mouse line with inducible, astrocyte-specific overexpression of the gap junction protein connexin43 (Cx43). In these mice, hippocampal astrocytes exhibited markedly elevated Cx43 protein levels and a ~ 20% increase in intercellular gap junction coupling. Enhanced coupling was accompanied by a reduction in astrocytic cell volume and branching, without affecting passive membrane properties or astrocyte density in the hippocampus. Cx43 overexpression had no detectable impact on adult neurogenesis in the dentate gyrus, nor did it alter hippocampal synaptic efficacy or plasticity. Notably, in a mouse model of temporal lobe epilepsy with hippocampal sclerosis, astrocytic Cx43 overexpression attenuated chronic epileptic activity and the extent of sclerosis, supporting an antiepileptic role of the astroglial network. Collectively, these findings enhance our understanding of the functional relevance of astrocytic gap junction coupling in health and disease, with potential implications for the design of new treatment strategies.
- Open Access
- 8 July 2025
- Published by Wiley in The Journal of Physiology
- Vol. 604 (4) , 1695-1707
Targeting necroptosis protects against astrocyte death and hippocampal sclerosis in experimental temporal lobe epilepsy
Temporal lobe epilepsy (TLE) is the most common and severe form of adult focal epilepsy and is frequently associated with hippocampal sclerosis (HS). Accumulating evidence suggests that brain inflammation plays an important pathophysiological role in TLE. A key pro‐inflammatory mediator is tumour necrosis factor α (TNFα), which can trigger necroptosis pathways regulated by RIPK1, RIPK3 and MLKL through binding to the TNF receptor 1 (TNFR1). Previously, we detected activation of RIPK1, RIPK3 and MLKL in hippocampal CA1 astrocytes, along with a reduction in astrocyte density, during the early stages of experimentally induced TLE‐HS, providing strong evidence for necroptotic astrocytic cell death. Using immunohistochemistry, pharmacology and long‐term EEG recording, here we unravel the mechanisms underlying necroptosis induction in astrocytes and its role in epileptogenesis. The results show that pharmacological inhibition of necroptosis using Nec‐1s, a specific inhibitor of RIPK1, or selective inhibition of soluble TNFα by XPro1595, as well as genetic knockout of TNFR1, effectively rescued CA1 astrocyte loss caused by kainate‐induced status epilepticus. Furthermore, targeting necroptosis by Nec‐1s administration attenuated CA1 astrogliosis, degeneration of pyramidal neurons, granular cell dispersion and shrinkage of the CA1 subfield. In contrast, Nec‐1s did not affect acute and chronic epileptic activity in the TLE‐HS model. Our findings demonstrate that TNFα‐induced necroptotic astrocyte death is involved in the pathogenesis of TLE. image Key points: In the early stage of experimental temporal lobe epilepsy with hippocampal sclerosis (TLE‐HS), we observed activation of RIPK1, RIPK3 and MLKL in CA1 astrocytes, along with a reduction in astrocyte density, providing evidence for necroptotic cell death. Pharmacological inhibition of necroptosis (Nec‐1s), blockade of soluble tumour necrosis factor α (XPro1595) or genetic knockout of TNFR1 prevented astrocyte loss after status epilepticus. Continuous telemetric EEG recordings showed that Nec‐1s has no effect on acute or chronic epileptic activity in the TLE‐HS model. Immunohistochemical analysis revealed that Nec‐1s treatment reduced the extent of hippocampal sclerosis in experimental TLE‐HS. Our results provide further insights into the molecular mechanisms underlying the development and progression of TLE.
- 8 July 2025
- Published by Wiley in The Journal of Physiology
- Vol. 604 (4) , 1695-1707
Open AccessTargeting necroptosis protects against astrocyte death and hippocampal sclerosis in experimental temporal lobe epilepsy
Temporal lobe epilepsy (TLE) is the most common and severe form of adult focal epilepsy and is frequently associated with hippocampal sclerosis (HS). Accumulating evidence suggests that brain inflammation plays an important pathophysiological role in TLE. A key pro‐inflammatory mediator is tumour necrosis factor α (TNFα), which can trigger necroptosis pathways regulated by RIPK1, RIPK3 and MLKL through binding to the TNF receptor 1 (TNFR1). Previously, we detected activation of RIPK1, RIPK3 and MLKL in hippocampal CA1 astrocytes, along with a reduction in astrocyte density, during the early stages of experimentally induced TLE‐HS, providing strong evidence for necroptotic astrocytic cell death. Using immunohistochemistry, pharmacology and long‐term EEG recording, here we unravel the mechanisms underlying necroptosis induction in astrocytes and its role in epileptogenesis. The results show that pharmacological inhibition of necroptosis using Nec‐1s, a specific inhibitor of RIPK1, or selective inhibition of soluble TNFα by XPro1595, as well as genetic knockout of TNFR1, effectively rescued CA1 astrocyte loss caused by kainate‐induced status epilepticus. Furthermore, targeting necroptosis by Nec‐1s administration attenuated CA1 astrogliosis, degeneration of pyramidal neurons, granular cell dispersion and shrinkage of the CA1 subfield. In contrast, Nec‐1s did not affect acute and chronic epileptic activity in the TLE‐HS model. Our findings demonstrate that TNFα‐induced necroptotic astrocyte death is involved in the pathogenesis of TLE. image Key points: In the early stage of experimental temporal lobe epilepsy with hippocampal sclerosis (TLE‐HS), we observed activation of RIPK1, RIPK3 and MLKL in CA1 astrocytes, along with a reduction in astrocyte density, providing evidence for necroptotic cell death. Pharmacological inhibition of necroptosis (Nec‐1s), blockade of soluble tumour necrosis factor α (XPro1595) or genetic knockout of TNFR1 prevented astrocyte loss after status epilepticus. Continuous telemetric EEG recordings showed that Nec‐1s has no effect on acute or chronic epileptic activity in the TLE‐HS model. Immunohistochemical analysis revealed that Nec‐1s treatment reduced the extent of hippocampal sclerosis in experimental TLE‐HS. Our results provide further insights into the molecular mechanisms underlying the development and progression of TLE.
- Open Access
Ablation of CCL17‐positive hippocampal neurons induces inflammation‐dependent epilepsy
Objective: Neuronal cell death and neuroinflammation are characteristic features of epilepsy, but it remains unclear whether neuronal cell death as such is causative for the development of epileptic seizures. To test this hypothesis, we established a novel mouse line permitting inducible ablation of pyramidal neurons by inserting simian diphtheria toxin (DT) receptor (DTR) cDNA into the Ccl17 locus. The chemokine CCL17 is expressed in pyramidal CA1 neurons in adult mice controlling microglial quiescence.Methods: Seizure activity in CCL17‐DTR mice was analyzed by electroencephalographic recordings following treatment with DT for 3 consecutive days. Neuroinflammation and neuronal cell death were evaluated by (immuno)histochemistry. Pharmacological inhibition of TNFR1 signaling was achieved by treatment with XPro1595, a dominant‐negative inhibitor of soluble tumor necrosis factor.Results: Neuronal cell death was detectable 7 days (d7) after the first DT injection in heterozygous CCL17‐DTR mice. Spontaneous epileptic seizures were observed in the vast majority of mice, often with an initial peak at d6–9, followed by a period of reduced activity and a gradual increase during the 1‐month observation period. Microglial reactivity was overt from d5 after DT administration not only in the CA1 region but also in the CA2/CA3 area, shortly followed by astrogliosis. Reactive microgliosis and astrogliosis persisted until d30 and, together with neuronal loss and stratum radiatum shrinkage, reflected important features of human hippocampal sclerosis. Granule cell dispersion was detectable only 3 months after DT treatment. Application of XPro1595 significantly reduced chronic seizure burden without affecting the development of hippocampal sclerosis.Significance: In conclusion, our data demonstrate that sterile pyramidal neuronal death is sufficient to cause epilepsy in the absence of other pathological processes. The CCL17‐DTR mouse line may thus be a valuable model for further mechanistic studies on epilepsy and assessment of antiseizure medication.
Open AccessAblation of CCL17‐positive hippocampal neurons induces inflammation‐dependent epilepsy
Objective: Neuronal cell death and neuroinflammation are characteristic features of epilepsy, but it remains unclear whether neuronal cell death as such is causative for the development of epileptic seizures. To test this hypothesis, we established a novel mouse line permitting inducible ablation of pyramidal neurons by inserting simian diphtheria toxin (DT) receptor (DTR) cDNA into the Ccl17 locus. The chemokine CCL17 is expressed in pyramidal CA1 neurons in adult mice controlling microglial quiescence.Methods: Seizure activity in CCL17‐DTR mice was analyzed by electroencephalographic recordings following treatment with DT for 3 consecutive days. Neuroinflammation and neuronal cell death were evaluated by (immuno)histochemistry. Pharmacological inhibition of TNFR1 signaling was achieved by treatment with XPro1595, a dominant‐negative inhibitor of soluble tumor necrosis factor.Results: Neuronal cell death was detectable 7 days (d7) after the first DT injection in heterozygous CCL17‐DTR mice. Spontaneous epileptic seizures were observed in the vast majority of mice, often with an initial peak at d6–9, followed by a period of reduced activity and a gradual increase during the 1‐month observation period. Microglial reactivity was overt from d5 after DT administration not only in the CA1 region but also in the CA2/CA3 area, shortly followed by astrogliosis. Reactive microgliosis and astrogliosis persisted until d30 and, together with neuronal loss and stratum radiatum shrinkage, reflected important features of human hippocampal sclerosis. Granule cell dispersion was detectable only 3 months after DT treatment. Application of XPro1595 significantly reduced chronic seizure burden without affecting the development of hippocampal sclerosis.Significance: In conclusion, our data demonstrate that sterile pyramidal neuronal death is sufficient to cause epilepsy in the absence of other pathological processes. The CCL17‐DTR mouse line may thus be a valuable model for further mechanistic studies on epilepsy and assessment of antiseizure medication.
- Open Access
Epileptic activity triggers rapid ROCK1‐dependent astrocyte morphology changes
Long‐term modifications of astrocyte function and morphology are well known to occur in epilepsy. They are implicated in the development and manifestation of the disease, but the relevant mechanisms and their pathophysiological role are not firmly established. For instance, it is unclear how quickly the onset of epileptic activity triggers astrocyte morphology changes and what the relevant molecular signals are. We therefore used two‐photon excitation fluorescence microscopy to monitor astrocyte morphology in parallel to the induction of epileptiform activity. We uncovered astrocyte morphology changes within 10–20 min under various experimental conditions in acute hippocampal slices. In vivo, induction of status epilepticus resulted in similarly altered astrocyte morphology within 30 min. Further analysis in vitro revealed a persistent volume reduction of peripheral astrocyte processes triggered by induction of epileptiform activity. In addition, an impaired diffusion within astrocytes and within the astrocyte network was observed, which most likely is a direct consequence of the astrocyte remodeling. These astrocyte morphology changes were prevented by inhibition of the Rho GTPase RhoA and of the Rho‐associated kinase (ROCK). Selective deletion of ROCK1 but not ROCK2 from astrocytes also prevented the morphology change after induction of epileptiform activity and reduced epileptiform activity. Together these observations reveal that epileptic activity triggers a rapid ROCK1‐dependent astrocyte morphology change, which is mechanistically linked to the strength of epileptiform activity. This suggests that astrocytic ROCK1 signaling is a maladaptive response of astrocytes to the onset of epileptic activity.
Open AccessEpileptic activity triggers rapid ROCK1‐dependent astrocyte morphology changes
Long‐term modifications of astrocyte function and morphology are well known to occur in epilepsy. They are implicated in the development and manifestation of the disease, but the relevant mechanisms and their pathophysiological role are not firmly established. For instance, it is unclear how quickly the onset of epileptic activity triggers astrocyte morphology changes and what the relevant molecular signals are. We therefore used two‐photon excitation fluorescence microscopy to monitor astrocyte morphology in parallel to the induction of epileptiform activity. We uncovered astrocyte morphology changes within 10–20 min under various experimental conditions in acute hippocampal slices. In vivo, induction of status epilepticus resulted in similarly altered astrocyte morphology within 30 min. Further analysis in vitro revealed a persistent volume reduction of peripheral astrocyte processes triggered by induction of epileptiform activity. In addition, an impaired diffusion within astrocytes and within the astrocyte network was observed, which most likely is a direct consequence of the astrocyte remodeling. These astrocyte morphology changes were prevented by inhibition of the Rho GTPase RhoA and of the Rho‐associated kinase (ROCK). Selective deletion of ROCK1 but not ROCK2 from astrocytes also prevented the morphology change after induction of epileptiform activity and reduced epileptiform activity. Together these observations reveal that epileptic activity triggers a rapid ROCK1‐dependent astrocyte morphology change, which is mechanistically linked to the strength of epileptiform activity. This suggests that astrocytic ROCK1 signaling is a maladaptive response of astrocytes to the onset of epileptic activity.
- Open Access
Role of Impaired Astrocyte Gap Junction Coupling in Epileptogenesis
The gap-junction-coupled astroglial network plays a central role in the regulation of neuronal activity and synchronisation, but its involvement in the pathogenesis of neuronal diseases is not yet understood. Here, we present the current state of knowledge about the impact of impaired glial coupling in the development and progression of epilepsy and discuss whether astrocytes represent alternative therapeutic targets. We focus mainly on temporal lobe epilepsy (TLE), which is the most common form of epilepsy in adults and is characterised by high therapy resistance. Functional data from TLE patients and corresponding experimental models point to a complete loss of astrocytic coupling, but preservation of the gap junction forming proteins connexin43 and connexin30 in hippocampal sclerosis. Several studies further indicate that astrocyte uncoupling is a causal event in the initiation of TLE, as it occurs very early in epileptogenesis, clearly preceding dysfunctional changes in neurons. However, more research is needed to fully understand the role of gap junction channels in epilepsy and to develop safe and effective therapeutic strategies targeting astrocytes.
Open AccessRole of Impaired Astrocyte Gap Junction Coupling in Epileptogenesis
The gap-junction-coupled astroglial network plays a central role in the regulation of neuronal activity and synchronisation, but its involvement in the pathogenesis of neuronal diseases is not yet understood. Here, we present the current state of knowledge about the impact of impaired glial coupling in the development and progression of epilepsy and discuss whether astrocytes represent alternative therapeutic targets. We focus mainly on temporal lobe epilepsy (TLE), which is the most common form of epilepsy in adults and is characterised by high therapy resistance. Functional data from TLE patients and corresponding experimental models point to a complete loss of astrocytic coupling, but preservation of the gap junction forming proteins connexin43 and connexin30 in hippocampal sclerosis. Several studies further indicate that astrocyte uncoupling is a causal event in the initiation of TLE, as it occurs very early in epileptogenesis, clearly preceding dysfunctional changes in neurons. However, more research is needed to fully understand the role of gap junction channels in epilepsy and to develop safe and effective therapeutic strategies targeting astrocytes.
- Open Access
- 30 January 2023
- Published by MDPI AG in Preprints.org
Role of Impaired Astrocyte Gap Junction Coupling in Epilepto-Genesis
The gap junction-coupled astroglial network plays a central role in the regulation of neuronal activity and synchronization, but its involvement in the pathogenesis of neuronal diseases is not yet understood. Here we present the current state of knowledge about the impact of impaired glial coupling in the development and progression of epilepsy and discuss whether astrocytes represent alternative therapeutic targets. We focus mainly on temporal lobe epilepsy (TLE), which is the most common form of epilepsy in adults, characterized by high therapy resistance. Functional data from TLE patients and corresponding experimental models point to a complete loss of astrocytic coupling, but preservation of the gap junction forming proteins connexin43 (Cx43) and connexin30 (Cx30) in hippocampal sclerosis. Several studies further indicate that astrocyte uncoupling represents a causal event in the initiation of TLE, as it occurs very early in epileptogenesis, clearly preceding dysfunctional changes in neurons. However, more research is needed to fully understand the role of gap junction channels in epilepsy and to develop safe and effective therapeutic strategies targeting astrocytes.
- 30 January 2023
- Published by MDPI AG in Preprints.org
Open AccessRole of Impaired Astrocyte Gap Junction Coupling in Epilepto-Genesis
The gap junction-coupled astroglial network plays a central role in the regulation of neuronal activity and synchronization, but its involvement in the pathogenesis of neuronal diseases is not yet understood. Here we present the current state of knowledge about the impact of impaired glial coupling in the development and progression of epilepsy and discuss whether astrocytes represent alternative therapeutic targets. We focus mainly on temporal lobe epilepsy (TLE), which is the most common form of epilepsy in adults, characterized by high therapy resistance. Functional data from TLE patients and corresponding experimental models point to a complete loss of astrocytic coupling, but preservation of the gap junction forming proteins connexin43 (Cx43) and connexin30 (Cx30) in hippocampal sclerosis. Several studies further indicate that astrocyte uncoupling represents a causal event in the initiation of TLE, as it occurs very early in epileptogenesis, clearly preceding dysfunctional changes in neurons. However, more research is needed to fully understand the role of gap junction channels in epilepsy and to develop safe and effective therapeutic strategies targeting astrocytes.